新華醫療(600587.SH):擬收購德國蛇牌公司所持的新華手術器械40%股權
格隆匯12月30日丨新華醫療(600587.SH)公佈,公司擬以人民幣4819.50萬元為依據,扣除應當代扣代繳的相關税費後,按照付款當日中國人民銀行公佈的當天外匯牌價進行換算對應的歐元收購德國蛇牌國際有限公司(“德國蛇牌公司”)所持有的新華手術器械有限公司(“新華手術器械”)40%股權。
新華手術器械作為新華醫療的起家產品,技術先進,產品種類齊全,廣獲臨牀及客户認可,此次收購完成後,新華手術器械將成為公司的全資子公司,可以聚焦公司主業發展,發揮品牌優勢,實現業務的協同發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.